Clinical Trials

Phase NA Not yet recruiting

Carcinoma, Hepatocellular

NCT07417800 2026-02-18

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

1,000 enrolled

Carcinoma, Hepatocellular

NCT06740370 2025-08-14

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

32 enrolled

Phase NA Not yet recruiting

Carcinoma, Hepatocellular

NCT07077798 2025-07-22

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

234 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT06622031 2025-01-13

TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

42 enrolled

Carcinoma, Hepatocellular

NCT05215665 2024-12-11

GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma

146 enrolled

Cholangiocarcinoma

NCT06061276 2024-09-23

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

40 enrolled

Carcinoma, Hepatocellular, Liver Diseases

NCT06070636 2024-08-09

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

30 enrolled

Carcinoma, Hepatocellular, Liver Diseases

NCT04618367 2024-03-06

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Phase NA Completed

30 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Phase NA Completed

23 enrolled

CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

NCT06277024 2024-02-26

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

50 enrolled

Stomach Neoplasms

NCT05444478 2023-11-07

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

274 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms, Recurrence

NCT04642547 2023-08-01

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Phase NA Completed

30 enrolled

Carcinoma, Hepatocellular

NCT04967495 2023-05-18

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

171 enrolled

Carcinoma, Hepatocellular

NCT05592197 2023-02-16

Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT

Phase NA Withdrawn

Advanced Hepatocellular Carcinoma

NCT05621499 2022-11-18

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

60 enrolled

Carcinoma, Hepatocellular

NCT03838796 2022-08-02

Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

297 enrolled

Carcinoma, Hepatocellular

NCT05391867 2022-05-26

Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma

70 enrolled

Carcinoma, Hepatocellular

NCT05339581 2022-04-27

iPLENTY-pvtt

78 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05162898 2022-01-27

Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

90 enrolled

Liver Neoplasms

NCT04443049 2021-10-05

To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.

170 enrolled

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT04531228 2021-09-22

Thalen

60 enrolled

Carcinoma, Hepatocellular

NCT04961138 2021-07-14

Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma

164 enrolled

Carcinoma, Hepatocellular

NCT04443322 2020-09-22

Dulect2020-1

20 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04444193 2020-06-23

Dulect2020-2